Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sonja J Gill"'
Autor:
Sonja J Gill, Jon Travers, Irina Pshenichnaya, Fiona A Kogera, Syd Barthorpe, Tatiana Mironenko, Laura Richardson, Cyril H Benes, Michael R Stratton, Ultan McDermott, Stephen P Jackson, Mathew J Garnett
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140988 (2015)
Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition and this is being evaluate
Externí odkaz:
https://doaj.org/article/b92378ffd7914656b8896f03d69dd08c
Autor:
Elisabetta Leo, Sabina Cosulich, James Yates, Joanne Wilson, Harriet Southgate, Aaron Smith, Mark J. O'Connor, Jenni Nikkilä, Gareth Maglennon, Ruth Macdonald, Emilyanne Leonard, Jeffrey Johannes, Kunzah Jamal, Glen Hawthorne, Stephen Fawell, Anna Cronin, Susan E. Critchlow, Lisa McWilliams, Andy Pike, Sonja J. Gill, Anna D. Staniszewska, Giuditta Illuzzi
Supplementary Data from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b51a5c301c6edc9e5d86cdcc1239b13
https://doi.org/10.1158/1078-0432.22488935.v1
https://doi.org/10.1158/1078-0432.22488935.v1
Autor:
Elisabetta Leo, Sabina Cosulich, James Yates, Joanne Wilson, Harriet Southgate, Aaron Smith, Mark J. O'Connor, Jenni Nikkilä, Gareth Maglennon, Ruth Macdonald, Emilyanne Leonard, Jeffrey Johannes, Kunzah Jamal, Glen Hawthorne, Stephen Fawell, Anna Cronin, Susan E. Critchlow, Lisa McWilliams, Andy Pike, Sonja J. Gill, Anna D. Staniszewska, Giuditta Illuzzi
Purpose:We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2, which has been shown to play a role in the survival of hematopoietic/ste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27d708dc305d7cfaab263c167f3caeef
https://doi.org/10.1158/1078-0432.c.6532832.v1
https://doi.org/10.1158/1078-0432.c.6532832.v1
Autor:
Elisabetta Leo, Sabina Cosulich, James Yates, Joanne Wilson, Harriet Southgate, Aaron Smith, Mark J. O'Connor, Jenni Nikkilä, Gareth Maglennon, Ruth Macdonald, Emilyanne Leonard, Jeffrey Johannes, Kunzah Jamal, Glen Hawthorne, Stephen Fawell, Anna Cronin, Susan E. Critchlow, Lisa McWilliams, Andy Pike, Sonja J. Gill, Anna D. Staniszewska, Giuditta Illuzzi
Supplementary Figure from Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::077a5ba1a2d0e13db736793ffd438973
https://doi.org/10.1158/1078-0432.22488920.v1
https://doi.org/10.1158/1078-0432.22488920.v1
Autor:
Jeffrey W. Johannes, Fiona Pachl, Amber Balazs, Tieguang Yao, C. Larner, Lisa McWilliams, Marianne Schimpl, Scott W. Martin, Kevin J. Embrey, Tom D. Heightman, Paul Hemsley, Jonathan P. Orme, Derek Barratt, Giuditta Illuzzi, Andrew Madin, Paolo Di Fruscia, Avipsa Ghosh, Martin J. Packer, Scott D. Edmondson, Elisabetta Leo, Xiaolan Zheng, Matthew D. Chuba, Xiaohui Pei, Mark J. O'Connor, Verity Talbot, Ke Zhang, Stephen Fawell, Elizabeth Underwood, Anna Staniszewska, Lina Liu, Lin Xue, Sonja J. Gill, Anders Gunnarsson, Andrew Pike, Susan E. Critchlow, Jeffrey G. Varnes, Andrew X. Zhang, Sébastien L. Degorce, J. Lane, Sudhir M. Hande, Hongyao She, Sabina Cosulich, Michal Bista
Publikováno v:
Journal of Medicinal Chemistry. 64:14498-14512
Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d5da59f02fe0bf1798c2492422c31c3
https://doi.org/10.1021/acs.jmedchem.1c01012
https://doi.org/10.1021/acs.jmedchem.1c01012
Autor:
Alan Lau, Susan Galbraith, Sonja J. Gill, Mark J. O'Connor, Joshua Armenia, Jacqueline H. L. Fok, Conchita Vens, Rebecca L. Lloyd, Jonathan Cairns, Jenni Nikkilä, Christopher J. Bakkenist, Paul W. G. Wijnhoven
Publikováno v:
Mol Cancer Ther
Radiotherapy is an effective anticancer treatment, but combinations with targeted agents that maximize efficacy while sparing normal tissue are needed. Here, we assess the radiopotentiation profiles of DNA damage response inhibitors (DDRi) olaparib (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::633fe37e32a0d72b0b66bc4989529109
https://doi.org/10.1158/1535-7163.mct-20-0502
https://doi.org/10.1158/1535-7163.mct-20-0502
Autor:
Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill, Andy Pike, Lisa McWilliams, Susan E. Critchlow, Anna Cronin, Stephen Fawell, Glen Hawthorne, Kunzah Jamal, Jeffrey Johannes, Emilyanne Leonard, Ruth Macdonald, Gareth Maglennon, Jenni Nikkilä, Mark J. O'Connor, Aaron Smith, Harriet Southgate, Joanne Wilson, James Yates, Sabina Cosulich, Elisabetta Leo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(21)
Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2, which has been shown to play a role in the survival of hematopoietic/st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f37f1456d11cb64b84480a9b2fa64b57
https://pubmed.ncbi.nlm.nih.gov/35929986
https://pubmed.ncbi.nlm.nih.gov/35929986
Autor:
Rebecca Sargeant, Ruth Macdonald, Jordan Pugh, Stewart Jones, Daniel Sutton, Emilyanne Leonard, Mark J. Anderton, Carmen Pin, James Atkinson, Rob Collins, Glen Hawthorne, Sarah Chinery, Sonja J. Gill, Andrew Pike, Peter Cotton, Gareth Maglennon
Publikováno v:
Cancer Research. 81:1374-1374
Current clinical poly (ADP-ribose) polymerase (PARP) inhibitors target both PARP1 and PARP2 and they all cause clinical cytopenias with varying severity. Understanding the mechanism underlying the hematological toxicity of these agents is key for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::623cbc36a0e0ecbd263b2129c95b6964
https://doi.org/10.1158/1538-7445.am2021-1374
https://doi.org/10.1158/1538-7445.am2021-1374
Autor:
Mark J. O'Connor, Philip B. Rawlins, Kevin J. Embrey, Anders Gunnarsson, Sudhir M. Hande, Anna Staniszewska, Fiona Pachl, Andrew X. Zhang, Jonathan P. Orme, Giuditta Illuzzi, Lisa McWilliams, Sonja J. Gill, Jeffrey W. Johannes, J. Lane, Sébastien L. Degorce, Amber Balazs, Martin J. Packer, Andrew Madin, Marianne Schimpl, Andrew Pike, Elisabetta Leo, Xiaolan Zheng, Avipsa Ghosh, C. Larner
Publikováno v:
Cancer Research. 81:296-296
Since the approval of olaparib in 2014 for BRCA mutated (BRCAm) ovarian cancer, many PARP inhibitors have been developed and have seen widespread success. However, as a class, these drugs are not without adverse events which have limited their abilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5541745268ca2c08d1cdc8f164ef2184
https://doi.org/10.1158/1538-7445.am2021-296
https://doi.org/10.1158/1538-7445.am2021-296
Autor:
Syd Barthorpe, Stephen P. Jackson, Jon Travers, Laura Richardson, Mathew J. Garnett, Irina Pshenichnaya, Fiona Kogera, Cyril H. Benes, Ultan McDermott, Michael R. Stratton, Tatiana Mironenko, Sonja J. Gill
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140988 (2015)
PLoS ONE
PLoS ONE
Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition and this is being evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ca96040928c34fc95ee3eb38e15512b
https://www.repository.cam.ac.uk/handle/1810/252693
https://www.repository.cam.ac.uk/handle/1810/252693